|
In May, a Bronchiectasis and NTM patient conference was held in Berkeley, California. At that conference, there was an inspiring discussion about CRISPR technology —  --the revolutionary gene‑editing tool that earned Drs. Jennifer Doudna and Emmanuelle Charpentier the 2020 Nobel Prize in Chemistry. And, coincidentally, Dr. Doudna’s academic home is right there in Berkeley, at the University of California — the very place where some of the world’s most exciting CRISPR research is unfolding. So what does this have to do with bronchiectasis and MAC? Researchers are now exploring ways to harness CRISPR’s power to improve both treatment and diagnosis for people living with these challenging lung conditions. CRISPR as a future treatment for bronchiectasisResearchers are investigating whether CRISPR gene editing could one day correct the underlying cellular or genetic mechanisms that drive bronchiectasis progression. For example:
CRISPR as a Diagnostic Tool for MAC InfectionsMAC (Mycobacterium avium complex) a stubborn cause of lung infections in bronchiectasis. Detecting MAC quickly and accurately is critical — yet current tests like sputum culture can take weeks, and many of us with “dry bronchiectasis” struggle to produce a sputum sample in the first place. Here’s where CRISPR‑based diagnostics come in:
Faster results mean earlier treatment and less waiting, which can make a real difference for people managing chronic infections. Final thoughtsCRISPR is still in its early days as it relates to bronchiectasis and MAC, but its potential is inspiring. From faster, more accurate diagnostics to the possibility of actually repairing or preventing airway damage at the genetic level, this technology could reshape what it means to live with chronic lung disease.
For now, staying informed about advances like these, and working closely with your care team, is one of the best ways to prepare for the future of bronchiectasis care. Science is moving forward, and so are we.
0 Comments
Many people assume it’s easy to tell the difference between a viral illness and a bacterial one.  But as Dr. Elisa Ignatius, an Infectious Disease expert specilaizing in bronchiectasis, at Johns Hopkins, explained at the Berkeley Patient Conference — it’s not always so clear-cut.
When you catch a respiratory virus, it doesn’t just make you feel lousy. Viruses like flu, RSV, and even the common cold can actually damage the lining of your airways, impair mucociliary clearance, and disrupt the function of immune cells that normally keep bacteria in check. This creates a vulnerable, “immunosuppressed” environment in the lungs and airways — giving bacteria that usually live harmlessly in your upper respiratory tract, like Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus, the perfect opportunity to multiply and cause secondary infection. That’s why what starts as a routine viral illness can sometimes lead to a bacterial superinfection. For people with conditions like bronchiectasis or COPD, this dynamic can make flare-ups more severe and harder to manage. One clinical clue that suggests bacterial infection has taken hold? The so-called “double dip” — when symptoms improve at first, then worsen again, especially with new or higher fever, more productive cough, thicker sputum, and increased fatigue. It’s not a perfect rule, and antibiotics aren’t always necessary, but recognizing these patterns can help patients and clinicians make smarter decisions about when to treat and when to wait. Awareness of how viral and bacterial infections interact is key to staying on top of your lung health and preventing complications. |
AuthorLinda Cooper Esposito, MPH is a health educator with bronchiectasis. She developed the BE CLEAR Method to Living with Bronchiectasis and writes with compassion and humor about this chronic lung disease. Archives
November 2025
Categories
All
|
RSS Feed